{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:45:36Z","timestamp":1768405536007,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011539","name":"University of Minnesota Masonic Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA-211256"],"award-info":[{"award-number":["CA-211256"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.omto.2023.01.005","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T03:15:19Z","timestamp":1674184519000},"page":"197-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-2974","authenticated-orcid":false,"given":"Valeria","family":"Guidolin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yupeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foster C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret L.","family":"MacMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Villalta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen S.","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7686-0504","authenticated-orcid":false,"given":"Silvia","family":"Balbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2023.01.005_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2174\/1568026619666190401100519","article-title":"Nitrogen mustards as anticancer chemotherapies: historic perspective, current developments and future\u00a0trends","volume":"19","author":"Diethelm-Varela","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.omto.2023.01.005_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","article-title":"Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.omto.2023.01.005_bib3","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1021\/ac902923s","article-title":"Quantitative high-performance liquid chromatography-electrospray ionization tandem mass spectrometry analysis of bis-N7-guanine DNA-DNA cross-links in white blood cells of cancer patients receiving cyclophosphamide therapy","volume":"82","author":"Malayappan","year":"2010","journal-title":"Anal. Chem."},{"key":"10.1016\/j.omto.2023.01.005_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/pbc.23254","article-title":"Formation of cyclophosphamide specific DNA adducts in hematological diseases","volume":"58","author":"Johnson","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omto.2023.01.005_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/acs.chemrestox.6b00380","article-title":"DNA adducts from anticancer drugs as candidate predictive markers for precision medicine","volume":"30","author":"Stornetta","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.omto.2023.01.005_bib6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ijc.30747","article-title":"A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer","volume":"141","author":"Wang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omto.2023.01.005_bib7","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1200\/JCO.2010.34.3616","article-title":"DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy","volume":"29","author":"Wang","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2023.01.005_bib8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1535-7163.MCT-16-0381","article-title":"Microdose-induced drug-DNA adducts as biomarkers of chemotherapy resistance in humans and mice","volume":"16","author":"Zimmermann","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omto.2023.01.005_bib9","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1021\/ac403565m","article-title":"Application of a high-resolution mass-spectrometry-based DNA adductomics approach for identification of DNA adducts in complex mixtures","volume":"86","author":"Balbo","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.omto.2023.01.005_bib11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","article-title":"Busulfan in hematopoietic stem cell transplantation","volume":"15","author":"Ciurea","year":"2009","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.omto.2023.01.005_bib12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425250903107764","article-title":"Busulfan in hematopoietic stem cell transplant setting","volume":"5","author":"McCune","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.omto.2023.01.005_bib13","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","article-title":"Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.omto.2023.01.005_bib14","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood.V94.11.3960a","article-title":"Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia","volume":"94","author":"Clift","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.omto.2023.01.005_bib15","first-page":"6203","article-title":"Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study","volume":"50","author":"Vassal","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2023.01.005_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.omto.2023.01.005_bib17","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1592\/phco.28.12.1502","article-title":"Optimal prevention of seizures induced by high-dose busulfan","volume":"28","author":"Eberly","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.omto.2023.01.005_bib18","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.omto.2023.01.005_bib19","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.omto.2023.01.005_bib20","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the American society for blood and marrow transplantation practice guidelines committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.omto.2023.01.005_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.omto.2023.01.005_bib22","first-page":"759","article-title":"Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?","volume":"14","author":"Schuler","year":"1994","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.omto.2023.01.005_bib23","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omto.2023.01.005_bib24","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","article-title":"Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review","volume":"13","author":"Myers","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.omto.2023.01.005_bib25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1349-7006.2004.tb03231.x","article-title":"DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect","volume":"95","author":"Iwamoto","year":"2004","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omto.2023.01.005_bib26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/biom11030366","article-title":"Identification of new markers of alcohol-derived DNA damage in humans","volume":"11","author":"Guidolin","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.omto.2023.01.005_bib27","doi-asserted-by":"crossref","first-page":"11706","DOI":"10.1021\/acs.analchem.5b02759","article-title":"Screening for DNA alkylation mono and cross-linked adducts with a comprehensive LC-MS3 adductomic approach","volume":"87","author":"Stornetta","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.omto.2023.01.005_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3389\/fchem.2019.00658","article-title":"Targeted high resolution LC\/MS3 adductomics method for the characterization of endogenous DNA damage","volume":"7","author":"Carr\u00e0","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.omto.2023.01.005_bib29","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1021\/acsinfecdis.0c00326","article-title":"Biosynthesis, mechanism of action, and inhibition of the enterotoxin tilimycin produced by the opportunistic pathogen Klebsiella oxytoca","volume":"6","author":"Alexander","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.omto.2023.01.005_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0090-9556(25)06715-7","article-title":"Urinary metabolites of busulfan in the rat","volume":"15","author":"Hassan","year":"1987","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omto.2023.01.005_bib31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF00558081","article-title":"Pharmacokinetic and metabolic studies of high-dose busulphan in adults","volume":"36","author":"Hassan","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.omto.2023.01.005_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1124\/dmd.106.012880","article-title":"Induction of glutathione synthesis explains pharmacodynamics of high-dose busulfan in mice and highlights putative mechanisms of drug interaction","volume":"35","author":"Bouligand","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omto.2023.01.005_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.abb.2015.08.005","article-title":"The busulfan metabolite EdAG irreversibly glutathionylates glutaredoxins","volume":"583","author":"Scian","year":"2015","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.omto.2023.01.005_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.dib.2015.09.002","article-title":"Supporting data for characterization of the busulfan metabolite EdAG and the Glutaredoxins that it adducts","volume":"5","author":"Scian","year":"2015","journal-title":"Data Brief"},{"key":"10.1016\/j.omto.2023.01.005_bib35","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/acs.biochem.6b00622","article-title":"The myeloablative drug busulfan converts cysteine to dehydroalanine and lanthionine in redoxins","volume":"55","author":"Scian","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.omto.2023.01.005_bib36","first-page":"4465","article-title":"Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards","volume":"9","author":"Souliotis","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.01.005_bib37","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/acs.chemrestox.6b00412","article-title":"DNA adduct profiles predict in\u00a0vitro cell viability after treatment with the experimental anticancer prodrug PR104A","volume":"30","author":"Stornetta","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.omto.2023.01.005_bib38","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1021\/acs.chemrestox.5b00297","article-title":"Characterization of nitrogen mustard formamidopyrimidine adduct formation of bis(2-chloroethyl)ethylamine with calf thymus DNA and a human mammary cancer cell line","volume":"28","author":"Gruppi","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.omto.2023.01.005_bib39","first-page":"4237","article-title":"Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in\u00a0vivo in mice","volume":"45","author":"Hemminki","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2023.01.005_bib40","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1021\/tx020044g","article-title":"Relative toxicities of DNA cross-links and monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C","volume":"15","author":"Palom","year":"2002","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.omto.2023.01.005_bib41","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12917-021-03062-x","article-title":"Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients","volume":"17","author":"Walters","year":"2021","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.omto.2023.01.005_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3343\/alm.2014.34.1.7","article-title":"Quantification of human plasma-busulfan concentration by liquid chromatography-tandem mass spectrometry","volume":"34","author":"Moon","year":"2014","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.omto.2023.01.005_bib43","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/acs.chemrestox.9b00007","article-title":"Mass spectrometric quantitation of pyridyloxobutyl DNA phosphate adducts in rats chronically treated with N'-nitrosonornicotine","volume":"32","author":"Li","year":"2019","journal-title":"Chem. Res. Toxicol."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:27:01Z","timestamp":1762496821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770523000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":42,"alternative-id":["S2372770523000074"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2023.01.005","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2023.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}]}}